Citigroup Inc Viridian Therapeutics, Inc.\De Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Citigroup Inc holds 46,217 shares of VRDN stock, worth $914,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,217

Previous 27,203 69.9%

Holding current value

$914,634

Previous $353,000 197.73%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$12.16 - $23.33 $231,210 - $443,596	19,014 Added 69.9%	46,217 $1.05 Million
Q2 2024 Aug 12, 2024	SELL	$11.6 - $17.26 $3.72 Million - $5.54 Million	-320,710 Reduced 92.18%	27,203 $353,000
Q1 2024 May 10, 2024	BUY	$17.09 - $23.82 $4.51 Million - $6.28 Million	263,626 Added 312.77%	347,913 $6.09 Million
Q4 2023 Feb 09, 2024	SELL	$11.12 - $22.5 $289,364 - $585,495	-26,022 Reduced 23.59%	84,287 $1.84 Million
Q3 2023 Nov 09, 2023	BUY	$15.16 - $24.7 $463,350 - $754,930	30,564 Added 38.33%	110,309 $1.69 Million
Q2 2023 Aug 10, 2023	SELL	$22.57 - $29.67 $1.99 Million - $2.62 Million	-88,356 Reduced 52.56%	79,745 $1.9 Million
Q1 2023 May 11, 2023	BUY	$25.04 - $37.6 $2.77 Million - $4.16 Million	110,746 Added 193.09%	168,101 $4.28 Million
Q4 2022 Feb 09, 2023	BUY	$18.78 - $29.74 $74,688 - $118,275	3,977 Added 7.45%	57,355 $1.68 Million
Q3 2022 Nov 10, 2022	BUY	$10.7 - $25.5 $551,199 - $1.31 Million	51,514 Added 2763.63%	53,378 $1.1 Million
Q2 2022 Aug 10, 2022	SELL	$9.55 - $19.0 $250,935 - $499,244	-26,276 Reduced 93.38%	1,864 $22,000
Q1 2022 May 12, 2022	BUY	$16.79 - $20.88 $222,568 - $276,785	13,256 Added 89.06%	28,140 $520,000
Q4 2021 Feb 10, 2022	BUY	$15.65 - $21.5 $232,934 - $320,006	14,884 New	14,884 $294,000

Others Institutions Holding VRDN

# of Institutions

179

Shares Held

76.8M

Call Options Held

581K

Put Options Held

439K

View Full List

About Viridian Therapeutics, Inc.\DE

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $789M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

More about VRDN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account